CTOs on the Move

ViroCyt

www.virocyt.com

 
ViroCyt is the leader in the field of rapid virus quantification. Our goal is to provide the tools that deliver meaningful improvements to mission critical processes, such as vaccine manufacturing, protein expression, antiviral development and other settings where viruses play a significant role.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.virocyt.com
  • 2100 Central Avenue Suite 103
    Boulder, CO USA 80301
  • Phone: 720.599.3700

Executives

Name Title Contact Details
Michael Olszowy
Chief Technology Officer Profile

Similar Companies

Ash Stevens Inc

Founded in 1962, Ash Stevens is a premier contract research organization that provides low-volume, high-value Active Pharmaceutical Ingredients (APIs). We understand the industry needs and utilize our expertise in pharmaceutical regulatory affairs to

Orchard Therapeutics

Orchard Therapeutics is a leading global fully integrated commercial-stage company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies. Orchard’s portfolio of autologous ex vivo gene therapy programs has demonstrated sustained clinical benefit in over 150 patients across five disease areas. These programs include Strimvelis®, the first autologous ex vivo gene therapy approved by the EMA in 2016, 3 programs in advanced registrational studies in MLD (metachromatic leukodystrophy), WAS (Wiskott Aldrich syndrome) and ADA-SCID (adenosine deaminase severe combined immunodeficiency), 2 other clinical programs in X-CGD (X-linked chronic granulomatous disease) and beta-thalassemia, as well as an extensive preclinical pipeline. The company is partnered with world-leading institutions in gene therapy, including University College London, Great Ormond Street Hospital, the University of Manchester and Central Manchester University Hospitals, the University of California Los Angeles and Boston Children’s Hospital, and Telethon Institute of Gene Therapy/Ospedale San Raffaele. Orchard is a publicly traded company (NASDAQ: ORTX) with offices in the UK and the US, including London, San Francisco and Boston.

Rare Cancer Research Foundation

The Rare Cancer Research Foundation (RCRF) is dedicated to curing rare cancers through strategic investments and innovative collaborations that catalyze effective research and accelerate deployment of promising therapies. While rare cancers accounted for just over 25 percent of all new cancer diagnoses in 2013, they comprised more than 40 percent of all cancer deaths. RCRF`s goal is to develop research infrastructure for each rare cancer.

MitoSciences Inc

MitoSciences Inc is a Eugene, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Accium BioSciences

Accium BioSciences is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.